Policy / Pricing SCOTUS won’t hear pharma’s IRA complaints PharmaphorumThe US Supreme Court has refused to consider lawsuits from pharma groups challenging Medicare's drug pricing negotiation powers.Read full story pharminent May 19, 2026 (Last updated: May 19, 2026) Pharmaphorum The US Supreme Court has refused to consider lawsuits from pharma groups challenging Medicare’s drug pricing negotiation powers. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: 225: An Interview With Craig Martin, Founder and CEO of the Orphan Therapeutics AcceleratorNext: Regeneron signs $2.32bn deal with Parabilis for Helicon conjugates Related Stories Policy / Pricing US generic tariff reprieve on the rocks as Trump proposes 100% rate in 2028 pharminent July 22, 2026 Policy / Pricing UK commits to pharma IP protection in Swiss trade deal pharminent July 16, 2026 Policy / Pricing Germany approves healthcare costs overhaul despite significant pharma opposition pharminent July 13, 2026
